Creative Medical Tech Holdings, Inc. (CELZ) is experiencing an 81% surge in shares on Thursday following the company's announcement of FDA approval for expanded access therapy utilizing CELZ-201, also referred to as ImmCelz.
This cell-based program aims to manage abnormal glucose tolerance and prevent Type 1 Diabetes Mellitus in high-risk individuals.
The FDA granted an Orphan Drug Designation for CELZ-201 the day before.
CELZ is trading on the Nasdaq at $8.64, up 81.51% or $3.88 per share. It has traded between $3.93 and $13.30 in the past 52-week period.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.